Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.
A B S T R A C T We have shown recently that norepinephrine stimulates muscle cell hypertrophy in primary cultures from the neonatal rat ventricle and that this stimulation is not blocked by the beta adrenergic antagonist propranolol. The present study was done to define the adrenergic specificity of the myocyte hypertrophic response to norepinephrine. 90% pure, single-cell cultures of nongrowing myocytes were maintained in serum-free medium 199 with transferrin and insulin. Myocyte size was quantitated 48 h after addition of adrenergic agents, by measuring cell volume, cell surface area, and cell protein. L-norepinephrine increased myocyte size to a maximum 150% of control; half-maximum effect was obtained at a concentration of 0.2 AM. This increase in cell size was inhibited by the nonselective alpha adrenergic antagonist phentolamine and by the alpha, adrenergic antagonists prazosin and terazosin; it was not inhibited by propranolol or by the alpha2 adrenergic antagonist yohimbine. The beta adrenergic agonist isoproterenol did not increase cell size. Thus, norepinephrine-stim- INTRODUCTION We have shown recently that myocyte (MC)' hypertrophy and its regulation can be studied in primary cultures obtained from neonatal rat hearts (1) . Norepinephrine (NE) stimulates MC hypertrophy, both in serum-supplemented cultures with enlarging MCs and in serum-free cultures (1) . MCs in serum-free cultures beat rarely and do not enlarge, but they are viable and responsive to growth stimulation by serum and by NE (1) . The hypertrophic effect of NE is not due to a sustained chronotropic action (1) and is not blocked by the beta adrenergic antagonist propranolol (1) . In this study, using serum-free cultures and several adrenergic antagonists, we show that the stimulation of MC hypertrophy by NE is an alpha, adrenergic response.
METHODS
Single-cell cultures were prepared from hearts of day-old rats as described previously (1, 2) , except that 5% serum was used during preplating, not 0.5%; this change reduced the nonmyocardial cells (NMCs) in the final cultures from 20-25% (1, 2) to 10% (Results). All experiments used serum-free cultures maintained in medium 199 (Hanks salts) with 10 Ag/ml human transferrin, 10 g/ml porcine insulin, 1.5 AM vitamin B12, and 50 U/ml penicillin (1) . Unless noted, the medium through culture day 3 also contained 0.1 mM bromodeoxyuridine (BrdU) to prevent NMC proliferation (1, 2) . The experimental protocol has been described (1) . Small aliquots of freshly prepared solutions of adrenergic agents or their diluent (control) were added to the nongrowing serum-free cultures after a medium change on day 4 , and MC size and cell number were determined 48 h later (1) .
To retard NE degradation, the medium contained 100 AM vitamin C and was kept at pH 7.3; NE concentration (radioenzymatic assay) through 48 h remained at least 75% of that originally present. The dishes from each culture preparation were allocated to separate experiments; each experiment comprised several groups of [3] [4] [5] [6] dishes and always included a control group and a group that received NE alone.
Three measures of MC size were used, as previously described and validated: total cell protein, MC surface area, and cell volume (1 (1) . The number of MCs and NMCs was counted for at least three dishes in each group, using phase-contrast microscopy; the accuracy and reproducibility of the method have been shown (1, 2) . Cell protein concentration in picograms per cell was obtained by dividing the group average microgram of protein per dish by the average total cell number (1) .
The sources of the adrenergic agents (4-6) were as follows: Table I ), but not by the nonselective beta adrenergic antagonist propranolol (Figs. 1, 3 , and 4, and Tables  I-III) or the alpha2 adrenergic antagonist yohimbine ( Fig. 1 and Table I ). The nonselective beta agonist isoproterenol did not increase cell protein significantly (Fig. 2) . Propranolol did not add to the inhibition of the NE effect by alpha adrenergic antagonists (Tables  I and II) , even when alpha adrenergic blockade was incomplete (Table II The various antagonists alone had no significant effect on MC size (Fig. 4 and Tables I and III; data for cell protein not shown). Absence of antagonist toxicity was also shown by the fact that inhibition of the NE effect was at least partly reversible. Cells were exposed to 2,uM phentolamine or terazosin for 24 h, then given fresh medium and tested for response to 2 ,uM NE; NE increased cell protein by 15-32% (P < 0.05 vs. control cells). Antagonism was specific for the effect of NE; MC hypertrophy induced by addition of serum (1) These data are from two culture preparations. The cells in A were treated with BrdU for the first three culture days; the cells in B were never exposed to BrdU. Final NE concentration was 2,M. The antagonists were 2,M, except in A prazosin and yohimbine were 0.2 iMM. The amount of diluent (control) was equivalent for all dishes. MCs were detached with trypsin 48 h after the compounds were added, and cell volume was determined microscopically. Volumes are the mean±SE of 200-400 cells in A and 100 cells in B.
ing cell numbers (1), and they further show that this hypertrophic effect of NE is an alpha, adrenergic response. The evidence is inhibition of the hypertrophic response to NE by phentolamine, terazosin, and prazosin but not by propranolol or yohimbine and failure of isoproterenol to elicit a hypertrophic response. We previously reported that propranolol did not block the hypertrophic effect of NE or isoproterenol in MC cultures (1). Isoproterenol stimulated hypertrophy less than did NE, and only with prolonged exposure in serum-supplemented medium (1); this effect of isoproterenol (1) may have been explained by the alpha adrenergic agonist activity of high concentrations of this agent (4). There are no other studies of the regulation of MC hypertrophy in culture by catecholamines. There is evidence that NE stimulates myocardial hypertrophy in vivo independent of hemodynamic changes (8) , but whether this response to NE is alpha or beta adrenergic has not been defined (8) . Hypertrophy induced by NE injections in vivo is not blocked by the nonselective beta adrenergic antagonist alprenolol (9) , and this is consistent with an alpha adrenergic mediated response. In contrast, isoproterenol induces myocardial hypertrophy in vivo, and propranolol antagonizes this effect (10) . However, NE release from adrenergic nerve endings and tyrosine hydroxylase activity in cervical sympathetic ganglia are also stimulated by isoproterenol and inhibited by propranolol (11, 12) . Our observation that isoproterenol does not stimulate hypertrophy in neuron-free heart cell cultures raises the possibility that isoproterenol produces hypertrophy in vivo indirectly, by increasing NE release.
Alpha, adrenergic receptors have been identified in cultured rat heart cells by radioligand binding (13) .
The number of alpha, adrenergic receptors in the intact heart is similar to the number of beta adrenergic receptors (5), but their function on myocardial cells has been unclear (4, 14) . Our results are consistent with the hypothesis that one function of alpha, adrenergic receptors is to mediate a myocardial hypertrophic response to NE. The peak concentration of NE in an autonomic nerve-smooth muscle synapse ranges from 0.3 to 10.0 MM (15) ; the approximate ECw0 for the alpha, adrenergic-mediated hypertrophic response we observed in culture is within this range. Myocardial glucose transport (16) and phosphofructokinase activity (17) may be under alpha adrenergic control. Activation of glucose transport and phosphofructokinase are early events when growth factors stimulate cell hyperplasia (18) . Since cells enlarge before division, these same events may be important when cells grow by hypertrophy. Other evidence besides our study for alpha adrenergic involvement in growth regulation is the inhibition by phentolamine of liver cell regeneration after partial hepatectomy (19) .
